Veracyte, Inc. (VCYT)
NASDAQ: VCYT · Real-Time Price · USD
29.88
-0.25 (-0.81%)
Mar 31, 2025, 10:05 AM EDT - Market open
Veracyte Employees
Veracyte had 824 employees as of December 31, 2024. The number of employees increased by 9 or 1.10% compared to the previous year.
Employees
824
Change (1Y)
9
Growth (1Y)
1.10%
Revenue / Employee
$540,976
Profits / Employee
$29,294
Market Cap
2.33B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
VCYT News
- 5 days ago - New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer - Business Wire
- 11 days ago - Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25 - Business Wire
- 4 weeks ago - Solid Growth, Soft Outlook: Why I'm Holding On Veracyte - Seeking Alpha
- 4 weeks ago - Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive - Benzinga
- 4 weeks ago - Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 5 weeks ago - Veracyte to Participate in Upcoming Investor Conferences - Business Wire
- 6 weeks ago - New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research - Business Wire